Goldman Sachs
INDV icon

Goldman Sachs’s Indivior Pharmaceuticals INDV Stock Holding History

Goldman Sachs’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-70,000
Closed -$2.51M – 6733
2025
Q4 		$2.51M Hold
70,000
– – ﹤0.01% 4372
2025
Q3 		$1.69M Buy
+70,000
New +$1.46M ﹤0.01% 4623

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's INDV Position: Q2 2026 in Review

Goldman Sachs reduced its Indivior Pharmaceuticals (INDV) stake by 71% in Q2 2026, selling an estimated $62.1M and leaving 696,268 shares worth $28.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2313.

Goldman Sachs first reported a position in INDV in Q2 2023 and has held it in 13 quarters since. The position peaked at $159M in Q3 2025. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Goldman Sachs held 696,268 shares of Indivior Pharmaceuticals worth $28.6M as of Q2 2026.
  • Goldman Sachs sold 1,712,897 Indivior Pharmaceuticals shares in Q2 2026, an estimated $62.1M.
  • Indivior Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2313 holding.
  • Goldman Sachs first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Goldman Sachs's Indivior Pharmaceuticals position peaked at $159M in Q3 2025.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.